Renal effects of targeted anticancer therapies

Adverse events from novel anticancer targeted agents represent a growing problem for oncologists and nephrologists, who should cooperate to recognize, understand and adequately treat toxic effectsThe management of novel targeted anticancer agents in patients with chronic kidney disease or receiving haemodialysis is challenging because of a shortage of specific dataRecognition and prompt and proactive management of kidney toxic effects is necessary to aid in the proper administration of life-prolonging oncological treatmentsNephrologists and oncologists should initially treat renal toxic effects related to targeted anticancer agents according to available guidelines, because oncological patients do not necessarily differ from other patients with nephropathyA subspeciality of onconephrology urgently needs to develop, as only close cooperation and cultural change will improve the management and outcomes of patients with both cancer and kidney disease